| Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML (NCT02926586) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2017-01-01 |
| Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients (NCT02462265) | Oshadi Drug Administration | 2017-01-01 |
| Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients (NCT03045627) | Shandong University | 2017-01-01 |
| Reflexology: An Intervention for Acute Myeloid Leukemia(AML) Patients (NCT02863302) | Rambam Health Care Campus | 2017-01-01 |
| Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) (NCT03026842) | The First Hospital of Jilin University | 2017-01-01 |
| A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia (NCT02975869) | Massachusetts General Hospital | 2017-01-01 |
| Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm (NCT03012672) | University of Washington | 2016-12-30 |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies (NCT02743351) | Fate Therapeutics | 2016-12-20 |
| Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101) (NCT02773732) | University of Florida | 2016-12-16 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT02728050) | University of Washington | 2016-12-01 |
| Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML (NCT03023384) | International Consortium on Acute Leukemias | 2016-12-01 |
| A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia (NCT02954653) | Pfizer | 2016-11-28 |
| Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations (NCT02298166) | University of Ulm | 2016-11-17 |
| A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) (NCT02864290) | Astellas Pharma Global Development, Inc. | 2016-11-10 |
| Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy (NCT02979548) | Dr Atul Sharma | 2016-11-01 |
| Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia (NCT02914977) | Tara Lin | 2016-11-01 |
| Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02971397) | Wake Forest University Health Sciences | 2016-11-01 |
| A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) (NCT02892318) | Hoffmann-La Roche | 2016-10-31 |
| A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) (NCT02842827) | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 2016-10-06 |
| A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML (NCT02708641) | Michael Boyiadzis | 2016-10-04 |
| Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+ (NCT02936089) | Nanfang Hospital, Southern Medical University | 2016-10-01 |
| CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML (NCT02944162) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-10-01 |
| Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML (NCT02937662) | Institute of Hematology & Blood Diseases Hospital, China | 2016-10-01 |
| Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant (NCT02771197) | Northside Hospital, Inc. | 2016-09-28 |
| G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor (NCT02933333) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2016-09-27 |
| A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT02807558) | Syros Pharmaceuticals | 2016-09-20 |
| Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery (NCT02767388) | University of Nebraska | 2016-09-01 |
| Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome (NCT02909972) | Aileron Therapeutics, Inc. | 2016-09-01 |
| Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02899286) | Bio-Cancer Treatment International Limited | 2016-09-01 |
| Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (NCT02668653) | Daiichi Sankyo | 2016-09-01 |
| Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT02834390) | Daiichi Sankyo Co., Ltd. | 2016-08-12 |
| Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML (NCT02891278) | Columbia University | 2016-08-11 |
| Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study (NCT02877277) | Rigshospitalet, Denmark | 2016-08-08 |
| A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia (NCT02848248) | Seagen Inc. | 2016-08-01 |
| Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid Leukemia (NCT02856204) | Stanford University | 2016-08-01 |
| Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia (NCT02873338) | Jazz Pharmaceuticals | 2016-08-01 |
| Decitabine and Talazoparib in Untreated AML and R/R AML (NCT02878785) | University of Maryland, Baltimore | 2016-08-01 |
| The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia (NCT03173612) | Institute of Hematology & Blood Diseases Hospital, China | 2016-08-01 |
| MRD-directed Therapy for Low-risk and Intermediate-risk AML. (NCT02870777) | Nanfang Hospital, Southern Medical University | 2016-08-01 |
| Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia (NCT03083054) | University of Campinas, Brazil | 2016-08-01 |
| Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance (NCT02756962) | Washington University School of Medicine | 2016-07-06 |
| Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients (NCT02845297) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-07-01 |
| A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02835729) | NewLink Genetics Corporation | 2016-07-01 |
| Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation (NCT02750254) | Washington University School of Medicine | 2016-06-27 |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant (NCT02684162) | M.D. Anderson Cancer Center | 2016-06-22 |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (NCT02665065) | Actinium Pharmaceuticals | 2016-06-01 |
| GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia (NCT02799147) | St. Petersburg State Pavlov Medical University | 2016-06-01 |
| IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up (NCT04242849) | Josep Carreras Leukaemia Research Institute | 2016-05-23 |
| Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT02676323) | St. Jude Children's Research Hospital | 2016-05-03 |
| Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial (NCT02561455) | Astellas Pharma Global Development, Inc. | 2016-05-03 |
| Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02785900) | Seagen Inc. | 2016-05-01 |
| NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents (NCT02763475) | Instituto de Investigación Hospital Universitario La Paz | 2016-05-01 |
| A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (NCT02859948) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2016-05-01 |
| The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens (NCT02413021) | Isfahan University of Medical Sciences | 2016-05-01 |
| Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation (NCT02719574) | Forma Therapeutics, Inc. | 2016-04-30 |
| FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia (NCT02392429) | National Cancer Institute (NCI) | 2016-04-20 |
| MCLA-117 in Acute Myelogenous Leukemia (NCT03038230) | Merus B.V. | 2016-04-01 |
| Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML (NCT02750995) | Daniel El Fassi | 2016-04-01 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) (NCT02610062) | Astellas Pharma Global Development, Inc. | 2016-03-29 |
| Alvocidib Biomarker-driven Phase 2 AML Study (NCT02520011) | Sumitomo Pharma America, Inc. | 2016-03-14 |
| A Study of PLX51107 in Advanced Malignancies (NCT02683395) | Plexxikon | 2016-03-01 |
| Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia (NCT02674763) | ImmunoGen, Inc. | 2016-03-01 |
| CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma (NCT02742727) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-03-01 |
| Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice (NCT02698124) | Ulsan University Hospital | 2016-03-01 |
| Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors (NCT02508038) | University of Wisconsin, Madison | 2016-02-12 |
| Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML (NCT02686593) | The University of Hong Kong | 2016-02-01 |
| Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) (NCT02588092) | ADC Therapeutics S.A. | 2016-02-01 |
| Hematopoietic Stem Cell Microtransplantation for in AML (NCT02676856) | Nanfang Hospital, Southern Medical University | 2016-02-01 |
| Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (NCT02494167) | Baylor College of Medicine | 2016-02-01 |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia (NCT02779283) | OHSU Knight Cancer Institute | 2016-01-13 |
| Analysis of T Cell Metabolism in Acute Myeloid Leukemia Patients (NCT04259372) | University of Freiburg | 2016-01-01 |
| IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT (NCT02671708) | Nanfang Hospital, Southern Medical University | 2016-01-01 |
| MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age (NCT02582359) | Massachusetts General Hospital | 2016-01-01 |
| Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia (NCT03181815) | Sun Yat-sen University | 2016-01-01 |
| Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia (NCT04369287) | Istituto Clinico Humanitas | 2016-01-01 |
| Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (NCT02521493) | Children's Oncology Group | 2015-12-23 |
| Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (NCT02159495) | City of Hope Medical Center | 2015-12-15 |
| Investigation of the Gut Microbiota in Patients With Acute Myeloid Leukemia (NCT03881826) | Université Catholique de Louvain | 2015-12-04 |
| Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML (NCT02560025) | Massachusetts General Hospital | 2015-12-01 |
| Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia (NCT02680951) | Emory University | 2015-12-01 |
| Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 (NCT02473146) | Versailles Hospital | 2015-11-18 |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02566304) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-11-13 |
| CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies (NCT02678338) | Gilead Sciences | 2015-11-01 |
| A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients (NCT02614560) | Seagen Inc. | 2015-11-01 |
| Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation (NCT02598752) | Memorial Sloan Kettering Cancer Center | 2015-11-01 |
| A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (NCT02498665) | Sumitomo Pharma America, Inc. | 2015-11-01 |
| Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia (NCT02573363) | University of Chicago | 2015-10-07 |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children (NCT02646839) | Michael Pulsipher | 2015-10-01 |
| Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML (NCT02461537) | DKMS gemeinnützige GmbH | 2015-09-17 |
| IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia (NCT02508324) | Weill Medical College of Cornell University | 2015-09-10 |
| Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant (NCT02485535) | University of Chicago | 2015-09-04 |
| Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML (NCT02229266) | Technische Universität Dresden | 2015-09-01 |
| BL-8040 Addition to Consolidation Therapy in AML Patients (NCT02502968) | Dr. Petra Tschanter | 2015-09-01 |
| Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients (NCT02400281) | Arog Pharmaceuticals, Inc. | 2015-09-01 |
| Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT02543879) | Forma Therapeutics, Inc. | 2015-09-01 |
| Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients (NCT02400255) | Arog Pharmaceuticals, Inc. | 2015-09-01 |
| A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML) (NCT02483312) | University Health Network, Toronto | 2015-09-01 |
| Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (NCT02544438) | BioSight Ltd. | 2015-09-01 |
| Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15) (NCT02527447) | National Heart, Lung, and Blood Institute (NHLBI) | 2015-08-18 |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (NCT02381548) | National Cancer Institute (NCI) | 2015-08-18 |